Triple Inhaler Therapy in Adolescents and Adults with Moderate and Severe Persistent Asthma

Mark S. L'Eplattenier, University of Lynchburg

GINA image Copyright Approval submitted as supplemental

Doctor of Medical Science program (DMSc)

Advisor - Dr. Laura Witte, PhD, PA-C

Abstract

Expert guidelines, metanalysis, and multiple randomized controlled trials have demonstrated the effectiveness of long-acting inhaled antimuscarinic agents (LAMA) as an additive medication in poorly controlled moderate and severe persistent asthma. LAMAs play an essential role in blocking acetylcholine binding to muscarinic receptors and reducing bronchoconstriction and mucous production. By adding this medication to other combination inhalers - long-acting beta-agonists (LABA) and inhaled corticosteroids (ICS), patients can utilize a triple inhaler to improve FEV1 values and decrease exacerbations. Current treatment guidelines allow clinicians to develop more personalized treatment plans for their asthmatic patients.

This paper has been withdrawn.